Pancreatic Cancer
Here below, you will find a list of all the latest content published on this website on the topic of Pancreatic Cancer. The content is published in chronological order. Find out more about our content categorisation .
-
« Previous
- 1
- 2
- ...
- 19
-
Next »
- Pancreatic cancer
- Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A pr...
- Preoperative neutrophil‐to‐lymphocyte ratio (NLR) predicts recurrence after surgery in patient with pancreatic neuroendocrine neoplasm (PanNEN)
- Clinical outcomes of second-line chemotherapy after progression on nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarc...
- Evaluation of the effect of cholesorption on the concentration of TNF-α in the serum of the blood in tumours of the biliopancreatoduodenal zone
- Genetic characteristics of participants in the Australian Pancreatic Screening Study
- The emerging role of third-line gemcitabine plus nab-paclitaxel in advanced pancreatic adenocarcinoma
- Durable response to second-line m-FOLFIRINOX for advanced pancreatic adenocarcinoma in patients with performance status of two or less
- Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metas...
- Prognostic usefulness of advanced lung cancer inflammation index in locally-advanced pancreatic carcinoma patients treated with radical chemoradiot...
- Pancreaticoduodenectomy versus combined neoadjuvant chemotherapy and pancreaticoduodenectomy: Survival patterns among patients with stage II & III...
- HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced...
- Prognostic impact of the C-reactive protein/albumin ratio in advanced pancreatic cancer treated with GEM plus nab-PTX or FOLFIRINOX: Based on the r...
- Details of response with first-line gemcitabine and nab-paclitaxel therapy in patients with advanced pancreatic cancer
- Clinical importance of the determination of interleukin-6 in bile and blood in tumours of biliopancreatoduodenal zone
- Real-world fusion landscape in advanced Chinese pancreatic cancer using next generation sequecing: A multicenter study
- Whole-exome sequencing of tumour-only samples reveals the association between somatic alterations and clinical features in pancreatic cancer
- Screening of prognostic molecular biomarker for resectable pancreatic cancer
- Postoperative metastasis prediction based on portal vein circulating tumor cells detected by flow cytometry in periampullary or pancreatic cancer
- Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metast...
- What’s new in metastatic pancreatic cancer management?
- Expert Opinion on ‘PARP inhibitors as targeted therapy for personalized medicine’ - Panel Discussion
- Plasma ctDNA RAS mutation analysis by digital polymerase chain reaction in patients with inoperable pancreatic cancer
- Exploring the role of the DDB2 protein as a potent molecular target in pancreatic ductal adenocarcinoma
- Not only gene mutation matters: Development of flow cytometry panel to determine BRCA2 deficiency for personalised therapy by PARP inhibitors in pa...
-
« Previous
- 1
- 2
- ...
- 19
-
Next »